Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Studies how amyotrophic lateral sclerosis develops and changes in people in mainland China

Observes how amyotrophic lateral sclerosis spreads and progresses in people across China.

Plain-language title generated from the registry record
Registry title: Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)

Key facts

Where
Beijing, ChinaSee the site

Where in China

  • Peking University Third HospitalBeijing, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Peking University Third Hospital
Trial code
NCT04454892
Record updated
2 July 2020
Original description
1. Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; 2. To investigate the cause of ALS in mainland China in the crowd disease development process and the corresponding characteristics change ; 3. To explore the effect of prognosis of ALS;Read full original descriptionShow less

A Study on the Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) in Mainland China

1. Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; 2. To investigate the cause of ALS in mainland China in the crowd disease development process and the corresponding characteristics change ; 3. To explore the effect of prognosis of ALS;

Inclusion: Patients were diagnosed with ALS recruited from all participant clinical centers.The diagnosis of ALS was made using the revised El Escorial criteria for definite, probable, lab-supported, and possible.

Exclusion: Decline to follow-up.

ClinicalTrials.gov NCT04454892